Subscribe to RSS
DOI: 10.1055/a-2649-9240
Small-Cell Lung Cancer Updates
Funding None.

Abstract
Small-cell lung cancer (SCLC) is a high-grade, aggressive neuroendocrine tumor with a particularly poor prognosis, characterized by early metastases and rapid development of therapy resistance. There have historically been few treatment options for advanced or extensive stage SCLC, which comprises 70% of patients at the time of diagnosis, and 5-year survival rates for these patients have been under 5% for decades. Treatment of SCLC is now undergoing rapid changes due to advances in the field and many promising clinical trials, with several new therapy approvals within the last year. Advanced SCLC treatment is now a combination of chemotherapy and immunotherapy in the first line, with multiple second and later-line options. Early-stage SCLC is treated with chemoradiation followed by consolidative immunotherapy, a change in practice based on a recent clinical trial demonstrating an improvement of almost 2 years in median overall survival. In the era of immunotherapy and novel agents, prognosis has improved for advanced-stage disease, with 3-year survival rates of 16 and 17% in clinical trials for chemoimmunotherapy combinations. Despite these advances, most patients will progress within 6 months of starting first-line chemoimmunotherapy; thus, this disease continues to represent an area of unmet need. This update will highlight current standard of care practices and updates of recent promising trials that have improved outcomes, including survival, for SCLC patients.
Keywords
small cell lung cancer - immunotherapy - antibody drug conjugate - anti-angiogenesis - bispecific T cell engager - reviewPublication History
Article published online:
07 August 2025
© 2025. Thieme. All rights reserved.
Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA
-
References
- 1 Lyon, France: International Agency for Research on Cancer FJ Ervik M, Lam F, Laversanne M, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F. Global Cancer Observatory Factsheet: Lung. Global Cancer Observatory: Cancer Today. 2024. Accessed September 10, 2024 at: https://gco.iarc.who.int/today
- 2 Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin 2024; 74 (01) 12-49
- 3 Tseng J-S, Chiang C-J, Chen K-C. et al. Association of smoking with patient characteristics and outcomes in small cell lung carcinoma, 2011-2018. JAMA Netw Open 2022; 5 (03) e224830
- 4 Kim SY, Park HS, Chiang AC. Small cell lung cancer. JAMA 2025; 333 (21) 1906-1917
- 5 Cittolin-Santos GF, Knapp B, Ganesh B. et al. The changing landscape of small cell lung cancer. Cancer 2024; 130 (14) 2453-2461
- 6 Farago AF, Keane FK. Current standards for clinical management of small cell lung cancer. Transl Lung Cancer Res 2018; 7 (01) 69-79
- 7 Fukuoka M, Furuse K, Saijo N. et al. Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer. J Natl Cancer Inst 1991; 83 (12) 855-861
- 8 Ardizzoni A, Hansen H, Dombernowsky P. et al. Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group. J Clin Oncol 1997; 15 (05) 2090-2096
- 9 Horn L, Mansfield AS, Szczęsna A. et al; IMpower133 Study Group. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med 2018; 379 (23) 2220-2229
- 10 Liu SV, Reck M, Mansfield AS. et al. Updated overall survival and PD-L1 subgroup analysis of patients with extensive-stage small-cell lung cancer treated with atezolizumab, carboplatin, and etoposide (IMpower133). J Clin Oncol 2021; 39 (06) 619-630
- 11 Paz-Ares L, Dvorkin M, Chen Y. et al; CASPIAN investigators. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet 2019; 394 (10212): 1929-1939
- 12 Paz-Ares L, Chen Y, Reinmuth N. et al. Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN. ESMO Open 2022; 7 (02) 100408
- 13 Fischer BM, Mortensen J, Langer SW. et al. A prospective study of PET/CT in initial staging of small-cell lung cancer: comparison with CT, bone scintigraphy and bone marrow analysis. Ann Oncol 2007; 18 (02) 338-345
- 14 Xanthopoulos EP, Corradetti MN, Mitra N. et al. Impact of PET staging in limited-stage small-cell lung cancer. J Thorac Oncol 2013; 8 (07) 899-905
- 15 National Comprehensive Cancer Network, Inc. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Small Cell Lung Cancer V.4.2025. Accessed January 13, 2025 at: https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1462
- 16 Nicholson SA, Beasley MB, Brambilla E. et al. Small cell lung carcinoma (SCLC): a clinicopathologic study of 100 cases with surgical specimens. Am J Surg Pathol 2002; 26 (09) 1184-1197
- 17 Kontogianni K, Nicholson AG, Butcher D, Sheppard MN. CD56: a useful tool for the diagnosis of small cell lung carcinomas on biopsies with extensive crush artefact. J Clin Pathol 2005; 58 (09) 978-980
- 18 Flamminio F, Tosi AL, Fellegara G. Crushing artifacts resulting in small blue cellular clusters that simulate small cell carcinoma. Int J Surg Pathol 2011; 19 (04) 487-491
- 19 Thunnissen E, Borczuk AC, Flieder DB. et al. The use of immunohistochemistry improves the diagnosis of small cell lung cancer and its differential diagnosis. an international reproducibility study in a demanding set of cases. J Thorac Oncol 2017; 12 (02) 334-346
- 20 Raso MG, Bota-Rabassedas N, Wistuba II. Pathology and classification of SCLC. Cancers (Basel) 2021; 13 (04) 820
- 21 Strimpakos A, Politi E, Kainis E. et al. The clinical significance of cytology versus histology-based diagnosis in small cell lung cancer: a retrospective study. Lung Cancer 2014; 85 (02) 186-190
- 22 Wang Y, Jin Y, Shen X. et al. POU2F3: a sensitive and specific diagnostic marker for neuroendocrine-low/negative small cell lung cancer. Am J Surg Pathol 2023; 47 (09) 1059-1066
- 23 Baine MK, Febres-Aldana CA, Chang JC. et al. POU2F3 in SCLC: clinicopathologic and genomic analysis with a focus on its diagnostic utility in neuroendocrine-low SCLC. J Thorac Oncol 2022; 17 (09) 1109-1121
- 24 Gay CM, Stewart CA, Park EM. et al. Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities. Cancer Cell 2021; 39 (03) 346-360.e7
- 25 Rosen RD, Sapra A. TNM Classification. In: StatPearls. StatPearls Publishing; 2025
- 26 Vallières E, Shepherd FA, Crowley J. et al; International Association for the Study of Lung Cancer International Staging Committee and Participating Institutions. The IASLC Lung Cancer Staging Project: proposals regarding the relevance of TNM in the pathologic staging of small cell lung cancer in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol 2009; 4 (09) 1049-1059
- 27 Chansky K, Detterbeck FC, Nicholson AG. et al. The IASLC lung cancer staging project: external validation of the revision of the TNM stage groupings in the eighth edition of the TNM classification of lung cancer. J Thorac Oncol 2017; 12 (07) 1109-1121
- 28 Detterbeck FC, Woodard GA, Bader AS. et al. The proposed ninth edition TNM classification of lung cancer. Chest 2024; 166 (04) 882-895
- 29 Detterbeck FC, Boffa DJ, Kim AW, Tanoue LT. The eighth edition lung cancer stage classification. Chest 2017; 151 (01) 193-203
- 30 Arriola E, Trigo JM, Sánchez-Gastaldo A. et al. Prognostic value of clinical staging according to TNM in patients with SCLC: a real-world surveillance epidemiology and end-results database analysis. JTO Clin Res Rep 2021; 3 (01) 100266
- 31 Yu JB, Decker RH, Detterbeck FC, Wilson LD. Surveillance epidemiology and end results evaluation of the role of surgery for stage I small cell lung cancer. J Thorac Oncol 2010; 5 (02) 215-219
- 32 Shaw J, Pundole X, Balasubramanian A. et al. Recent treatment patterns and real-world survival following first-line anti-PD-L1 treatment for extensive-stage small cell lung cancer. Oncologist 2024; 29 (12) 1079-1089
- 33 Tartarone A, Lerose R, Ardito R. et al. Long-term survival in small cell lung cancer: a case report and review of the literature. Future Oncol 2014; 10 (04) 523-528
- 34 Lababede O, Meziane MA. The eighth edition of TNM staging of lung cancer: reference chart and diagrams. Oncologist 2018; 23 (07) 844-848
- 35 Micke P, Faldum A, Metz T. et al. Staging small cell lung cancer: veterans administration lung study group versus international association for the study of lung cancer–what limits limited disease?. Lung Cancer 2002; 37 (03) 271-276
- 36 Cohen S, Brennan B, Banerjee M, Kalemkerian GP. Temporal trends in small cell lung cancer: analysis of the U.S. surveillance, epidemiology and end results (SEER) database. JCO 2023; 41 (16, suppl): e20641-e20641
- 37 Jeon DS, Kim HC, Kim SH. et al; Korean Association for Lung Cancer, Korea Central Cancer Registry. Five-year overall survival and prognostic factors in patients with lung cancer: results from the Korean Association of Lung Cancer Registry (KALC-R) 2015. Cancer Res Treat 2023; 55 (01) 103-111
- 38 Cheng Y, Spigel DR, Cho BC. et al; ADRIATIC Investigators. Durvalumab after chemoradiotherapy in limited-stage small-cell lung cancer. N Engl J Med 2024; 391 (14) 1313-1327
- 39 Carvajal-Hausdorf D, Altan M, Velcheti V. et al. Expression and clinical significance of PD-L1, B7-H3, B7-H4 and TILs in human small cell lung Cancer (SCLC). J Immunother Cancer 2019; 7 (01) 65
- 40 Paz-Ares L, Garassino MC, Chen Y. et al. Durvalumab ± tremelimumab + platinum-etoposide in extensive-stage small cell lung cancer (CASPIAN): outcomes by PD-L1 expression and tissue tumor mutational burden. Clin Cancer Res 2024; 30 (04) 824-835
- 41 Xie M, Vuko M, Rodriguez-Canales J. et al. Molecular classification and biomarkers of outcome with immunotherapy in extensive-stage small-cell lung cancer: analyses of the CASPIAN phase 3 study. Mol Cancer 2024; 23 (01) 115
- 42 Nabet BY, Hamidi H, Lee MC. et al. Immune heterogeneity in small-cell lung cancer and vulnerability to immune checkpoint blockade. Cancer Cell 2024; 42 (03) 429-443.e4
- 43 Liu SV, Mok TSK, Nabet BY. et al. Clinical and molecular characterization of long-term survivors with extensive-stage small cell lung cancer treated with first-line atezolizumab plus carboplatin and etoposide. Lung Cancer 2023; 186: 107418
- 44 Sutherland KD, Proost N, Brouns I, Adriaensen D, Song J-Y, Berns A. Cell of origin of small cell lung cancer: inactivation of Trp53 and Rb1 in distinct cell types of adult mouse lung. Cancer Cell 2011; 19 (06) 754-764
- 45 Rekhtman N, Tischfield SE, Febres-Aldana CA. et al. Chromothripsis-mediated small cell lung carcinoma. Cancer Discov 2025; 15 (01) 83-104
- 46 Poirier JT, Gardner EE, Connis N. et al. DNA methylation in small cell lung cancer defines distinct disease subtypes and correlates with high expression of EZH2. Oncogene 2015; 34 (48) 5869-5878
- 47 Dowlati A, Lipka MB, McColl K. et al. Clinical correlation of extensive-stage small-cell lung cancer genomics. Ann Oncol 2016; 27 (04) 642-647
- 48 Rudin CM, Poirier JT, Byers LA. et al. Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data. Nat Rev Cancer 2019; 19 (05) 289-297
- 49 Baine MK, Hsieh M-S, Lai WV. et al. SCLC subtypes defined by ASCL1, NEUROD1, POU2F3, and YAP1: a comprehensive immunohistochemical and histopathologic characterization. J Thorac Oncol 2020; 15 (12) 1823-1835
- 50 Simone II CB, Bogart JA, Cabrera AR. et al. Radiation therapy for small cell lung cancer: an ASTRO clinical practice guideline. Pract Radiat Oncol 2020; 10 (03) 158-173
- 51 Wong AT, Rineer J, Schwartz D, Schreiber D. Assessing the impact of postoperative radiation therapy for completely resected limited-stage small cell lung cancer using the national cancer database. J Thorac Oncol 2016; 11 (02) 242-248
- 52 Higgins K, Hu C, Ross HJ. et al. Concurrent chemoradiation ± atezolizumab (atezo) in limited-stage small cell lung cancer (LS-SCLC): results of NRG oncology/alliance LU005. Int J Radiat Oncol Biol Phys 2024; 120 (02) 2
- 53 Faivre-Finn C, Snee M, Ashcroft L. et al; CONVERT Study Team. Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial. Lancet Oncol 2017; 18 (08) 1116-1125
- 54 Walls GM, Mistry H, Barlesi F. et al. Long-term outcomes after concurrent once- or twice-daily chemoradiation in limited-stage small cell lung cancer: a brief report from the CONVERT trial. Int J Radiat Oncol Biol Phys 2024; 119 (05) 1386-1390
- 55 Bogart J, Wang X, Masters G. et al. High-dose once-daily thoracic radiotherapy in limited-stage small-cell lung cancer: CALGB 30610 (Alliance)/RTOG 0538. J Clin Oncol 2023; 41 (13) 2394-2402
- 56 Bogart JA, Waqar SN, Mix MD. Radiation and systemic therapy for limited-stage small-cell lung cancer. J Clin Oncol 2022; 40 (06) 661-670
- 57 Farrell MJ, Yahya JB, Degnin C. et al. Radiation dose and fractionation for limited-stage small-cell lung cancer: survey of US radiation oncologists on practice patterns. Clin Lung Cancer 2019; 20 (01) 13-19
- 58 Wilke C, Grosshans D, Duman J, Brown P, Li J. Radiation-induced cognitive toxicity: pathophysiology and interventions to reduce toxicity in adults. Neuro-oncol 2018; 20 (05) 597-607
- 59 Buczek D, Zaucha R, Jassem J. Neurotoxicity-sparing radiotherapy for brain metastases in breast cancer: a narrative review. Front Oncol 2024; 13: 1215426
- 60 Aupérin A, Arriagada R, Pignon JP. et al; Prophylactic Cranial Irradiation Overview Collaborative Group. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. N Engl J Med 1999; 341 (07) 476-484
- 61 Takahashi T, Yamanaka T, Seto T. et al. Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 2017; 18 (05) 663-671
- 62 Taylor JM, Rusthoven CG, Moghanaki D. Prophylactic cranial irradiation or MRI surveillance for extensive stage small cell lung cancer. J Thorac Dis 2020; 12 (10) 6225-6233
- 63 Brown PD, Gondi V, Pugh S. et al; for NRG Oncology. Hippocampal avoidance during whole-brain radiotherapy plus memantine for patients with brain metastases: phase III trial NRG oncology CC001. J Clin Oncol 2020; 38 (10) 1019-1029
- 64 Rodríguez de Dios N, Couñago F, Murcia-Mejía M. et al. Randomized phase III trial of prophylactic cranial irradiation with or without hippocampal avoidance for small-cell lung cancer (PREMER): a GICOR-GOECP-SEOR study. J Clin Oncol 2021; 39 (28) 3118-3127
- 65 Reck M, Dziadziuszko R, Sugawara S. et al. Five-year survival in patients with extensive-stage small cell lung cancer treated with atezolizumab in the phase III IMpower133 study and the Phase III IMbrella a extension study. Lung Cancer 2024; 196: 107924
- 66 Reinmuth N, Goldman JW, Garassino MC. et al. 141O durvalumab (D) ± tremelimumab (T) + platinum-etoposide (EP) in 1L extensive-stage (ES) SCLC: characteristics of long- term survivors in the CASPIAN study. Ann Oncol 2022; 33: S97-S98
- 67 Vince M, Naqvi SMH, Pellini B, Verbosky M, Melzer D. Real-world comparison of the efficacy and safety of atezolizumab versus durvalumab in extensive-stage small cell lung cancer. Lung Cancer 2024; 198: 107999
- 68 Zou Y, Ren X, Zhang H. et al. Efficacy and safety of durvalumab + chemotherapy vs. atezolizumab + chemotherapy in the treatment of small-cell lung cancer: a retrospective comparative cohort study. J Thorac Dis 2023; 15 (06) 3339-3349
- 69 Cheng Y, Han L, Wu L. et al; ASTRUM-005 Study Group. Effect of first-line serplulimab vs placebo added to chemotherapy on survival in patients with extensive-stage small cell lung cancer: the ASTRUM-005 randomized clinical trial. JAMA 2022; 328 (12) 1223-1232
- 70 Wang J, Zhou C, Yao W. et al; CAPSTONE-1 Study Group. Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2022; 23 (06) 739-747
- 71 Cheng Y, Fan Y, Zhao Y. et al; RATIONALE-312 Study Group. Tislelizumab plus platinum and etoposide versus placebo plus platinum and etoposide as first-line treatment for extensive-stage SCLC (RATIONALE-312): a multicenter, double-blind, placebo-controlled, randomized, phase 3 clinical trial. J Thorac Oncol 2024; 19 (07) 1073-1085
- 72 Trigo J, Subbiah V, Besse B. et al. Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial. Lancet Oncol 2020; 21 (05) 645-654
- 73 Subbiah V, Paz-Ares L, Besse B. et al. Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment. Lung Cancer 2020; 150: 90-96
- 74 Besse B, Paz-Ares LG, Peters S. et al. A phase III study of lurbinectedin alone or in combination with irinotecan vs investigator's choice (topotecan or irinotecan) in patients with relapsed small cell lung cancer (SCLC; LAGOON trial). JCO 2023; 41 (16, suppl): TPS8613-TPS8613
- 75 Paz-Ares L, Champiat S, Lai WV. et al. Tarlatamab, a first-in-class DLL3-targeted bispecific T-cell engager, in recurrent small-cell lung cancer: an open-label, phase i study. J Clin Oncol 2023; 41 (16) 2893-2903
- 76 Ahn M-J, Cho BC, Felip E. et al; DeLLphi-301 Investigators. Tarlatamab for patients with previously treated small-cell lung cancer. N Engl J Med 2023; 389 (22) 2063-2075
- 77 Morris EC, Neelapu SS, Giavridis T, Sadelain M. Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. Nat Rev Immunol 2022; 22 (02) 85-96
- 78 Sheth VS, Gauthier J. Taming the beast: CRS and ICANS after CAR T-cell therapy for ALL. Bone Marrow Transplant 2021; 56 (03) 552-566
- 79 Jain MD, Smith M, Shah NN. How I treat refractory CRS and ICANS after CAR T-cell therapy. Blood 2023; 141 (20) 2430-2442
- 80 Antonia SJ, López-Martin JA, Bendell J. et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncol 2016; 17 (07) 883-895
- 81 Chung HC, Piha-Paul SA, Lopez-Martin J. et al. Pembrolizumab after two or more lines of previous therapy in patients with recurrent or metastatic SCLC: results from the KEYNOTE-028 and KEYNOTE-158 studies. J Thorac Oncol 2020; 15 (04) 618-627
- 82 Owonikoko TK, Park K, Govindan R. et al. Nivolumab and ipilimumab as maintenance therapy in extensive-disease small-cell lung cancer: CheckMate 451. J Clin Oncol 2021; 39 (12) 1349-1359
- 83 Spigel DR, Vicente D, Ciuleanu TE. et al. Second-line nivolumab in relapsed small-cell lung cancer: CheckMate 331. Ann Oncol 2021; 32 (05) 631-641
- 84 Rudin CM, Awad MM, Navarro A. et al; KEYNOTE-604 Investigators. Pembrolizumab or placebo plus etoposide and platinum as first-line therapy for extensive-stage small-cell lung cancer: randomized, double-blind, phase III KEYNOTE-604 study. J Clin Oncol 2020; 38 (21) 2369-2379
- 85 Gitlitz BJ, Moon J, Glisson BS. et al. Sorafenib in platinum-treated patients with extensive stage small cell lung cancer: a Southwest Oncology Group (SWOG 0435) phase II trial. J Thorac Oncol 2010; 5 (11) 1835-1840
- 86 Spigel DR, Townley PM, Waterhouse DM. et al. Randomized phase II study of bevacizumab in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer: results from the SALUTE trial. J Clin Oncol 2011; 29 (16) 2215-2222
- 87 Tiseo M, Boni L, Ambrosio F. et al. Italian, multicenter, phase III, randomized study of cisplatin plus etoposide with or without bevacizumab as first-line treatment in extensive-disease small-cell lung cancer: the GOIRC-AIFA FARM6PMFJM trial. J Clin Oncol 2017; 35 (12) 1281-1287
- 88 Pujol JL, Lavole A, Quoix E. et al; French Cooperative Thoracic Intergroup (IFCT). Randomized phase II-III study of bevacizumab in combination with chemotherapy in previously untreated extensive small-cell lung cancer: results from the IFCT-0802 trial†. Ann Oncol 2015; 26 (05) 908-914
- 89 Lin C-S, Liu T-C, Lee M-T, Yang S-F, Tsao TC-Y. Independent prognostic value of hypoxia-inducible factor 1-alpha expression in small cell lung cancer. Int J Med Sci 2017; 14 (08) 785-790
- 90 Lin Q, Choyke PL, Sato N. Visualizing vasculature and its response to therapy in the tumor microenvironment. Theranostics 2023; 13 (15) 5223-5246
- 91 Munksgaard Persson M, Johansson ME, Monsef N. et al. HIF-2α expression is suppressed in SCLC cells, which survive in moderate and severe hypoxia when HIF-1α is repressed. Am J Pathol 2012; 180 (02) 494-504
- 92 Meder L, Schuldt P, Thelen M. et al. Combined VEGF and PD-L1 blockade displays synergistic treatment effects in an autochthonous mouse model of small cell lung cancer. Cancer Res 2018; 78 (15) 4270-4281
- 93 Fan Y, Zhao J, Wang Q. et al. Camrelizumab plus apatinib in extensive-stage SCLC (PASSION): a multicenter, two-stage, phase 2 trial. J Thorac Oncol 2021; 16 (02) 299-309
- 94 Stefanou D, Batistatou A, Arkoumani E, Ntzani E, Agnantis NJ. Expression of vascular endothelial growth factor (VEGF) and association with microvessel density in small-cell and non-small-cell lung carcinomas. Histol Histopathol 2004; 19 (01) 37-42
- 95 Subramanian M, Kabir AU, Barisas D, Krchma K, Choi K. Conserved angio-immune subtypes of the tumor microenvironment predict response to immune checkpoint blockade therapy. Cell Rep Med 2023; 4 (01) 100896
- 96 Lamberti G, Rihawi K, Riccardi F. et al. Carboplatin, etoposide, bevacizumab, and atezolizumab in patients with extensive-stage SCLC - GOIRC-01–2019 CeLEBrATE trial. J Thorac Oncol 2023; 18 (11) S168-S169
- 97 Ohe Y, Han B, Nishio M. et al. BEAT-SC: a randomized phase III study of bevacizumab or placebo in combination with atezolizumab and platinum-based chemotherapy in patients with extensive-stage small cell lung cancer (ES-SCLC). JCO 2024; 42 (16, suppl): 8001-8001
- 98 Han B, Ohe Y, Nishio M. et al. Second OS interim analysis from BEAT-SC: a randomized phase III study of bevacizumab (bev) or placebo in combination with atezolizumab and platinum-based chemotherapy in patients with extensive-stage small cell lung cancer (ES-SCLC). Ann Oncol 2024; 35: S1063-S1064
- 99 Cheng Y, Chen J, Zhang W. et al. Benmelstobart, anlotinib and chemotherapy in extensive-stage small-cell lung cancer: a randomized phase 3 trial. Nat Med 2024; 30 (10) 2967-2976
- 100 Xiong A, Wang L, Chen J. et al. Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China. Lancet 2025; 405 (10481): 839-849
- 101 Fang W, Zhao Y, Luo Y. et al; HARMONi-A Study Investigators. Ivonescimab plus chemotherapy in non-small cell lung cancer with EGFR variant: a randomized clinical trial. JAMA 2024; 332 (07) 561-570
- 102 Chen Z, Wu L, Wang Q. et al. Brief Report: ivonescimab combined with etoposide plus carboplatin as first-line treatment for extensive-stage SCLC: results of a phase 1b clinical trial. J Thorac Oncol 2025; 20 (02) 233-239
- 103 Fu Z, Li S, Han S, Shi C, Zhang Y. Antibody drug conjugate: the “biological missile” for targeted cancer therapy. Signal Transduct Target Ther 2022; 7 (01) 93
- 104 Dowlati A, Chiang AC, Cervantes A. et al. Phase 2 open-label study of sacituzumab govitecan as second-line therapy in patients with extensive-stage SCLC: results from TROPiCS-03. J Thorac Oncol 2025; 20 (06) 799-808
- 105 Johnson ML, Zvirbule Z, Laktionov K. et al. Rovalpituzumab tesirine as a maintenance therapy after first-line platinum-based chemotherapy in patients with extensive-stage-SCLC: results from the phase 3 MERU study. J Thorac Oncol 2021; 16 (09) 1570-1581
- 106 Blackhall F, Jao K, Greillier L. et al. Efficacy and safety of rovalpituzumab tesirine compared with topotecan as second-line therapy in DLL3-high SCLC: Results from the phase 3 TAHOE study. J Thorac Oncol 2021; 16 (09) 1547-1558
- 107 Owonikoko TK, Byers LA, Cheng Y. et al. IDeate-Lung02: a phase 3, randomized, open-label study of ifinatamab deruxtecan (I-DXd) vs treatment of physician's choice (TPC) in relapsed small cell lung cancer (SCLC). JCO 2024; 42 (16, suppl): TPS8126-TPS8126
- 108 Rudin CM, Ahn MJ, Johnson M. et al. Ifinatamab deruxtecan (I-DXd) in extensive- stage small cell lung cancer (ES-SCLC): interim analysis of ideate-lung01. J Thorac Oncol 2024; 19 (10) S15-S16
- 109 Chandana SR, Choudhury NJ, Dowlati A. et al. First-in-human study of ABBV-706, a seizure-related homolog protein 6 (SEZ6)–targeting antibody-drug conjugate (ADC), in patients (pts) with advanced solid tumors. JCO 2024; 42 (16, suppl): 3001-3001
- 110 Chandana S, Garmezy B, Dowlati A. et al. 2029TiP phase I study of ABBV-706, an anti- SEZ6 antibody-drug conjugate, alone or in combination in adults with advanced solid tumors. Ann Oncol 2023; 34: S1077
- 111 Chen M, Chen R, Jin Y. et al. Cold and heterogeneous T cell repertoire is associated with copy number aberrations and loss of immune genes in small-cell lung cancer. Nat Commun 2021; 12 (01) 6655
- 112 Chen Y, Li H, Fan Y. Shaping the tumor immune microenvironment of SCLC: mechanisms, and opportunities for immunotherapy. Cancer Treat Rev 2023; 120: 102606
- 113 Perol M, Ahn MJ, Cheng Y. et al. P1.13A.02 tarlatamab plus durvalumab as first-line maintenance in extensive-stage small cell lung cancer: DeLLphi-305 phase 3 trial. J Thorac Oncol 2024; 19 (10) S206-S207
- 114 Peters S, Champiat S, Yoshida T. et al. DAREON-8: a phase I, open-label, dose escalation/expansion trial of the DLL3-targeting T-cell engager, BI 764532, combined with first-line (1L) standard of care (platinum, etoposide, and anti-PD-L1 antibody) in patients (pts) with extensive-stage small cell lung carcinoma (ES-SCLC). JCO 2024; 42 (16, suppl): TPS8127-TPS8127
- 115 Molloy ME, Aaron WH, Barath M. et al. HPN328, a trispecific T cell-activating protein construct targeting DLL3-expressing solid tumors. Mol Cancer Ther 2024; 23 (09) 1294-1304
- 116 Beltran H, Johnson ML, Jain P. et al. Updated results from a phase 1/2 study of HPN328, a tri-specific, half-life (T1/2) extended DLL3-targeting T-cell engager in patients (pts) with small cell lung cancer (SCLC) and other neuroendocrine cancers (NEC). JCO 2024; 42 (16, suppl): 8090-8090
- 117 Tully KM, Tendler S, Carter LM. et al. Radioimmunotherapy targeting delta-like ligand 3 in small cell lung cancer exhibits antitumor efficacy with low toxicity. Clin Cancer Res 2022; 28 (07) 1391-1401
- 118 Krebs MG, Delord J-P, Jeffry Evans TR. et al. Olaparib and durvalumab in patients with relapsed small cell lung cancer (MEDIOLA): An open-label, multicenter, phase 1/2, basket study. Lung Cancer 2023; 180: 107216
- 119 Lok BH, Gardner EE, Schneeberger VE. et al. PARP inhibitor activity correlates with SLFN11 expression and demonstrates synergy with temozolomide in small cell lung cancer. Clin Cancer Res 2017; 23 (02) 523-535
- 120 Abdel Karim NF, Miao J, Reckamp KL. et al. SWOG S1929: phase II randomized study of maintenance atezolizumab (A) versus atezolizumab + talazoparib (AT) in patients with SLFN11 positive extensive stage small cell lung cancer (ES-SCLC). JCO 2023; 41 (16, suppl): 8504-8504
- 121 Chiang A. S2409 PRISM Trial. Presented at the: SWOG Spring Group Meeting Lung Committee; April 2024; Seattle.
- 122 Desai PA, Takahashi N, Lissa D. et al. Tazemetostat in combination with topotecan and pembrolizumab in patients with recurrent small cell lung cancer. JCO 2024; 42 (16, suppl): TPS8130-TPS8130
- 123 Cheng Y, Wang Q, Li K. et al. Anlotinib vs placebo as third- or further-line treatment for patients with small cell lung cancer: a randomised, double-blind, placebo-controlled Phase 2 study. Br J Cancer 2021; 125 (03) 366-371